Effects of citalopram and fluoxetine on the corticocerebral blood flow in conscious rabbits

Acta Physiologica Hungarica

Volumn 94, Issue 3, 2007, Pages 167-177

  Sas, Katalin ^a,c   Csete, K ^a   Vezekenyi Z ^a   Sztriha, L ^a   Vecsei L ^a   Papp, J Gy ^a,b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c NONE   (Hungary)

Author keywords

Citalopram; Conscious; Corticocerebral blood flow; Fluoxetine; Hydrogen polarography; Rabbits

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; ARTICLE; BLOOD PRESSURE; BRAIN CIRCULATION; BRAIN CORTEX; BRAIN ISCHEMIA; CAROTID ARTERY; CONSCIOUSNESS; DEPRESSION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART RATE; LIGATION; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RABBIT; VASCULARIZATION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PRESSURE; BRAIN ISCHEMIA; CAROTID ARTERIES; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; CITALOPRAM; CONSCIOUSNESS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FLUOXETINE; HEART RATE; LIGATION; RABBITS; SEROTONIN UPTAKE INHIBITORS;

EID: 34848916035     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.94.2007.3.1     Document Type: Article

References (40)

1. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M: 'Vascular depression' hypothesis. Arch. Gen. Psychiatry 54, 915-922 (1997)
2. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M: Clinically defined vascular depression. Am. J. Psychiatry 154, 562-565 (1997)
3. Andersen G, Vestergaard K, Lauritzen L: Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 25, 1099-1104 (1994)
4. Aukland K, Bower BF, Berliner RW: Measurement of local blood flow with hydrogen gas. Circ. Res. 14, 164-187 (1964)
5. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, Garcia Rodríguez LA, Christensen K, Gaist D: Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 33, 465-473 (2002)
6. Bonne O, Krausz Y: Pathophysiological significance of cerebral perfusion abnormalities in major depression-trait or state marker. Eur. Neuropsychopharmacol. 7, 2251-233 (1997)
7. Bonne O, Krausz Y, Aharon Y, Gelfin Y, Chisin R, Lerer B: Clinical doses of fluoxetine and cerebral blood flow in healthy volunteers. Psychopharmacology (Berl.) 143, 24-28 (1999)
8. Boyeson MG, Harmon RL, Jones JL: Comparative effects of fluoxetine, amitriptyline and serotonin on functional motor recovery after sensorimotor cortex injury. Am. J. Phys. Med. Rehabil. 73, 76-83 (1994)
9. Brust P, Friedrich A, Krizbai IA, Bergmann R, Roux F, Ganapathy V, Johannsen B: Functional expression of the serotonin transporter in immortalized rat brain microvessel endothelial cells. J. Neurochem. 74, 1241-1248 (2000)
10. Csete K, Papp JG: Effects of moxonidine on corticocerebral blood flow under normal and ischemic conditions in conscious rabbits. J. Cardiovasc. Pharmacol. 35, 417-421 (2000)
11. Folstein M, Maiberger R, McHugh P: Mood disturbance as specific complication in stroke. J. Neurol. Neurosurg. Psychiatry 40, 1018-1020 (1977)
12. Gainotti G, Azzoni A, Marra C: Frequency, phenomenology and anatomical-clinical correlates of major post-stroke depression. Br. J. Psychiatry 175, 163-167 (1999)
13. Gelfin Y, Gorfine M, Lerer B: Effect of clinical doses of fluoxetine on psychological variables in healthy volunteers. Am. J. Psychiatry 155, 290-292 (1998)
14. House A, Dennis M, Warlow C, Hawton K, Molyneux A: Mood disorders after stroke and their relation to lesion location. A CT scan study. Brain 113, 1113-1129 (1990)
15. Kitazono T, Ibayashi S, Nagao T, Kagiyama T, Kitayama J, Fujishima M: Role of tyrosine kinase in serotonin-induced constriction of the basilar artery in vivo. Stroke 29, 494-498 (1998)
16. Lesser IM, Mena I, Boone KB, Miller BL, Mehringer CM, Wohl M: Reduction of cerebral blood flow in older depressed patients. Arch. Gen. Psychiatry 51, 677-686 (1994)
17. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR: Nortriptyline treatment of post-stroke depression: a double-blind study. Lancet 11, 297-300 (1984)
18. Lou HC, Edvinsson L: Influence of serotinin and norepinephrine on flow capacity/pressure characteristics of feline isolated cerebral arteries. Stroke 17, 91-94 (1986)
19. Mast BT, Vedrody S: Poststroke depression: a biopsychosocial approach. Curr. Psychiatry Rep. 8, 25-33 (2006)
20. McDonald DA, Potter JM: The distribution of blood to the brain. J. Physiol. 114, 356-364 (1951)
21. Mirzoian RS, Topchian AV, Ganshina TS, Kostochka LM: Tropoxin and cerebrovascular effects of serotonin. Eksp. Klin. Farmakol. 63, 21-23 (2000)
22. Monnier M, Gangloff H (1961): Atlas for stereotaxic brain research on the conscious rabbit. In: Rabbit brain research (Vol 1), Elsevier Publishing, Amsterdam, pp. 1-76
23. Nakata N, Kato H, Kogure K: Protective effects of serotonin reuptake inhibitors, citalopram and clomipramine, against hippocampal CA1 neuronal damage following transient ischemia in the gerbil. Brain Res. 590, 48-52 (1992)
24. Neu P, Schlattman P, Schilling A, Hartmann A: Cerebrovascutar reactivity in major depression: a pilot study. Psychosom. Med. 66, 6-8 (2004)
25. Nobler MS, Olvet KR, Sackeim HA: Effects of medications on cerebral blood flow in late-life depression. Curr. Psychiatry Rep. 4, 51-58 (2002)
26. Pacher P, Ungvari Z, Kecskemeti V, Furst S: Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr. Med. Chem. 5, 381-390 (1998)
27. Robinson RG: Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol. Psychiatry 54, 376-387 (2003)
28. Robinson RG, Bolduc PL, Price TR: Two-year longitudinal study of poststroke mood disorders: diagnosis and outcome at one and two years. Stroke 18, 837-843 (1987)
29. Robinson RG, Kubos KL, Starr LB, Rao K, Price TR: Mood disorders in stroke patients. Importance of location of lesion. Brain 107, 81-93 (1984)
30. Sackeim HA, Prohovnik I, Moeller JR, Brown RP, Apter S, Prudic J, Devanand DP, Mukherjee S: Regional cerebral blood flow in mood disorders. I. Comparison of major depressives and normal controls at rest Arch. Gen. Psychiatry 47, 60-70 (1990)
31. Terstappen GC, Pellacani A, Aldegheri L, Graziani F, Carignani C, Pula G, Virginio C: The antidepressant fluoxetine blocks the human small conductance calcium-activated potassium channels. SK1, SK2 and SK3. Neurosci. Lett. 346, 85-88 (2003)
32. Tiemeier H, Bakker SLM, Hofman A, Koudstaal PJ, Breteler MMB: Cerebral haemodynamics and depression in the elderly. J. Neurol. Neurosurg. Psychiatry 73, 34-39 (2002)
33. Turner-Stokes L, Hassan N: Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 1: Diagnosis, frequency and impact. Clin. Rehabil. 16, 231-247 (2002)
34. Turner-Stokes L, Hassan N. Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives. Clin. Rehabil. 16, 248-260 (2002)
35. 2+ channel opener. Stroke 30, 1949-1954 (1999)
36. Van de Meent H, Geurts AC, Van Limbeek J: Pharmacologic treatment of poststroke depression: a systematic review of the literature. Top Stroke Rehabil. 10, 73-92 (2003)
37. Vanhoutte PM: Vascular effects of serotonin and ischemia. J. Cardiovasc. Pharmacol. 16 (Suppl 3), S15-S19 (1990)
38. Wegener G, Volke V, Harvey BH, Rosenberg R: Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res. 959, 128-134 (2003)
39. Whyte EM, Mulsant BH: Post stroke depression: epidemiology, pathophysiolqgy, and biological treatment. Biol. Psychiatry 52, 253-264 (2002)
40. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M: Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 31, 1829-1832 (2000)